Aug. 5 at 3:48 PM
$CLDX Don’t let the prurigo nodularis results make you shy on the upcoming Barzolvolimab phase 3 readout for Chronic Spontaneous Urticaria. Mast cells and the plasma cells that activate them are undoubtedly the main driver of CSU, with the mast cell degranulation being the cause of the symptoms. In contrast, PU has T cell and eosinophil involvement.
Not only is Barzo positioned for best in class in CSU but even seems to even lead to disease remission in some patients. Phase 2 tracking showed that while mast cells repopulated skin after the drug was discontinued, about half the patients remained free of symptoms. This effect was thought to be due to inflammatory reset making the autoantibodies an insufficient signal to restart inflammatory cascades (healthy donors also frequently have autoantibodies). For patients that had their hives come back, a second treatment was just as effective as the first.
Phase 3 readout in Q4 2026. Get excited.
